Symbiotec Pharmalab IPO

Symbiotec Pharmalab IPO is a book-built issue worth ₹1,757 crore, comprising a fresh issue of 15.21 lakh shares aggregating to ₹150 crore and an offer for sale of 1.63 crore shares worth ₹1,607 crore.  

The IPO will open for subscription on August 24, 2026, and close on August 27, 2026. The basis of allotment is expected to be finalised on August 28, 2026, while the shares are proposed to be listed on NSE and BSE on September 1, 2026. The IPO has a price band of ₹938 to ₹988 per share, with a lot size of 15 shares. Retail investors need to invest a minimum of ₹14,820 based on the upper price band. JM Financial Ltd., Avendus Capital Pvt. Ltd., Motilal Oswal Investment Advisors Ltd. and Nomura Financial Advisory & Securities (India) Pvt. Ltd. are the book-running lead managers, while MUFG Intime India Pvt. Ltd. is the registrar to the issue. 

Industry Outlook 

1. The global active pharmaceutical ingredients (API) market was valued at around USD 305.5 billion in 2025 and is projected to reach USD 424.6 billion by 2030, growing at a 6.8% CAGR. 
2. Small-molecule APIs accounted for nearly 64.3% of the global API market in 2025, while biological APIs increased their share from 26.5% in 2020 to 35.7% in 2025. Rising chronic diseases and growing demand for generic medicines are supporting market growth. 
3. Symbiotec Pharmalab operates in the specialised corticosteroid API segment, which was valued at around USD 421.2 million in 2025 and is estimated to grow at a 1.6%–3.0% CAGR between 2025 and 2030. 
4. Demand for corticosteroid APIs is supported by their use in respiratory, dermatology, ophthalmology and inflammatory disorders. The increasing prevalence of autoimmune conditions is also expected to sustain demand for these treatments. 
5. The CDMO market is projected to grow at a CAGR of 8.2%, creating opportunities for pharmaceutical companies with specialised manufacturing capabilities. 
6. India offers structural advantages for contract manufacturing, including lower setup costs, affordable utilities and access to cost-effective raw materials. 
7. Following the commissioning of its Ujjain and Mhow facilities, Symbiotec has 700 KL of industrial-scale fermentation capacity, positioning it to cater to demand across APIs, fermentation-based products and complex injectables. 

Symbiotec Pharmalab IPO Objectives  

The company plans to utilise the net proceeds from the IPO for the following purposes: 

1. The company plans to use ₹112.50 crore from the net IPO proceeds to prepay or repay, fully or partially, certain outstanding borrowings. 
2. The remaining proceeds will be utilised for general corporate purposes. 

About Symbiotec Pharmalab Limited  

Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company involved in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products for domestic and international markets. With more than 30 years of industry experience, the company has grown from a lab-scale steroidal hormone API manufacturer established in 1995 into a large-scale, backward-integrated manufacturing platform. It holds approvals from regulatory bodies and organisations including the US FDA, EU-GMP and South Korea’s Ministry of Food and Drug Safety.  

As of June 30, 2025, Symbiotec operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres. The company focuses on research-led manufacturing, quality compliance and sustainable production practices, serving the pharmaceutical, nutraceutical and wellness industries. Its key strengths include its strong position in corticosteroid and steroidal hormone APIs, long-standing customer relationships, vertically integrated manufacturing capabilities, established regulatory track record and continued investment in research and development. The company also aims to leverage its scientific expertise and existing capabilities to expand into new markets and develop intellectual property-led products. 

How To Check the Allotment Status of the Symbiotec Pharmalab IPO? 

Steps to check IPO allotment status on Angel One’s app: 

1. Log in to the Angel One app.
2. Go to the IPO Section and then to IPO Orders.
3. Select the individual IPO that you had applied for and check the allotment status.
4. Angel One will notify you of your IPO allotment status via push notification and email. 

Don't miss the next investment opportunity - browse the Upcoming IPO on Angel One. 

How To Apply for Symbiotec Pharmalab IPO Online? 

1. Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
2. Locate the IPO Section: Navigate to the 'IPO' section on the platform.
3. Select IPO: Find and select the Symbiotec Pharmalab IPO from the list of open IPOs.
4. Enter the Lot Size: Specify the number of lots you want to bid for.
5. Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
6. Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN. 

Contact Details of Symbiotec Pharmalab IPO  

Registered Office: Symbiotec Pharmalab Ltd. Address- 385/2, Pigdamber, Rau, Mhow, 

Indore, Madhya Pradesh, 453331 

Phone: +91 731 667 6405 

E-mail:secretarial@symbiotec.com 

Symbiotec Pharmalab IPO Reservation 

Symbiotec Pharmalab IPO Promoter Holding 

The promoters of the company are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP. 

Symbiotec Pharmalab IPO Prospectus 

• Symbiotec Pharmalab IPO DRHP 

Symbiotec Pharmalab IPO Registrar and Lead Managers 

Symbiotec Pharmalab IPO Lead Managers 

• JM Financial Ltd.
• Avendus Capital Pvt.Ltd.
• Motilal Oswal Investment Advisors Ltd.
• Nomura Financial Advisory & Securities (India) Pvt.Ltd. 

Registrar for Symbiotec Pharmalab IPO 

MUFG Intime India Pvt.Ltd. 

• Contact Number: 022-49186000
• Email Address: symbiotecpharmalab.ipo@in.mpms.mufg.com 

Financial Performance of Symbiotec Pharmalab Limited 

Symbiotec Pharmalab IPO Peer Comparison  

Strengths and Opportunities of Symbiotec Pharmalab IPO 

1. Symbiotec Pharmalab has a strong global position in corticosteroid and steroidal hormone APIs. 
2. The company has built long-term relationships with domestic and international customers. 
3. Its vertically integrated, multi-scale manufacturing platform is supported by sustainable practices and a strong regulatory track record. 
4. The company continues to invest in research and development (R&D) and has strong technological capabilities compared with Indian industry peers. 
5. Symbiotec aims to leverage its scientific expertise and existing capabilities to expand its addressable market and develop intellectual property-led products. 
6. The company has strong financial performance, supported by healthy gross margins, efficient capital utilisation and strong cash conversion. 
7. Its experienced leadership team is supported by a strong management pool and established institutional investors.
8. The company plans to strengthen its global leadership by expanding its steroidal hormone product portfolio across its API and ingredients businesses. 
9. It intends to leverage its fermentation capabilities to expand into biotechnology products, including GLP-1 and insulin. 
10. Symbiotec plans to commercialise complex injectables through differentiated drug-device combinations.  

Risks and Threats of Symbiotec Pharmalab IPO  

1. The company is heavily dependent on API sales, which accounted for 96.07% of revenue from operations in FY2026. Its top five APIs contributed 62.27% of revenue, making the business vulnerable to changes in demand or production disruptions. 
2. The company operates in a highly regulated industry, and its manufacturing facilities are subject to inspections and audits by regulatory authorities and customers. Any quality or compliance failure could lead to regulatory action, loss of approvals, reputational damage or business disruption. 
3. With 67.04% of FY2026 revenue coming from overseas customers, the company is exposed to risks related to international markets, including regulatory changes, economic conditions, geopolitical developments, currency movements and trade restrictions. 
4. Changes in US tariffs and anti-outsourcing policies could increase the cost of exports and reduce the competitiveness of the company's products in the US and other markets. 
5. The company depends significantly on a limited number of customers, with its top 10 customers contributing 57.59% of product sales in FY2026. Loss of key customers or a reduction or delay in orders could adversely affect revenue and profitability. 
6. All of the company's manufacturing facilities and dedicated R&D centres are located in Madhya Pradesh, creating geographical concentration risk. Natural disasters, power or water disruptions, machinery breakdowns, industrial accidents or other regional events could interrupt operations. 
7. The company relies on certain suppliers for raw materials, with its top 10 suppliers accounting for 25.50% of total expenses in FY2026. Supply disruptions, supplier failures or higher raw material costs could affect production and margins. 
8. The company operates in a competitive API and CDMO market, where competitors may have greater financial, technological, manufacturing, R&D and marketing resources. Failure to introduce products, adopt new technologies or compete effectively on pricing could affect growth. 
9. The company sources some raw materials from China, the US and other countries, exposing it to supply-chain disruptions arising from geopolitical developments, regulatory changes, trade restrictions or changes in import laws.
10. The company's growth depends on its ability to successfully develop and commercialise new products. Delays in R&D, unsuccessful product development, failure to obtain regulatory approvals or higher development costs could affect future growth and profitability.